

# Human DLL1/Delta1 Protein

Cat. No. DLL-HM101

## Description

<b>Source</b>	Recombinant Human DLL1/Delta1 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gln18-Gly540.
<b>Accession</b>	NP_005609
<b>Molecular Weight</b>	The protein has a predicted MW of 57.6 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

## Formulation and Storage


<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in 50mM Tris, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
<b>Reconstitution</b>	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage</b>	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

DLL1, a Notch signaling ligand, is significantly overexpressed in ERα luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor prognosis in ERα luminal breast cancer, but not in other subtypes of breast cancer. In addition, this effect is specific to DLL1, as other Notch ligands (DLL3, JAGGED1, and JAGGED2) do not influence the clinical outcome of ERα patients. DLL1-mediated Notch signaling in breast cancer is important for tumor cell proliferation, angiogenesis, and cancer stem cell function.

## Assay Data


### Tris-Bis PAGE



Human DLL1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC

Assay Data



The purity of Human DLL1 is greater than 95% as determined by SEC-HPLC.